The global post polycythemia vera myelofibrosis (PPV MF) market is anticipated to grow at a considerable CAGR of 9.1% during the forecast period (2022-2028). The increasing prevalence of chronic blood disorders is acting as the prime factor impacting the growth. As per the information provided by the Centers for Disease Control and Prevention in 2019, sickle cell disease is a blood disorder that affects more than 100,000 people in the US. Furthermore, next-generation sequencing (NGS) has identified multiple somatic mutations in MPNs and has contributed substantially to our understanding of disease pathogenesis, highlighting the role of clonal evolution in disease progression. Moreover, disease prognostication has expanded from encompassing only clinical decision-making to including genomics in prognostic scoring systems. Thus, these are the above factors mentioned which will further drive the PPV MF market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/post-polycythemia-vera-myelofibrosis-ppv-mf-market
However, a side effect from durvalumab is expected to hamper the growth of the market. Such Side effects are, bladder pain, bloating or swelling of the face, arms, hands, lower legs, or feet, bloody or cloudy urine, depressed mood, difficulty during urination, dry skin and hair, feeling cold, difficulty having a bowel movement, and others.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Abbvie Inc., Celgene Corp., CTI BioPharma Corp., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and Others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Report Segment
By Type
- Durvalumab
- Givinostat
- Glasdegib
- Idelalisib
- IMG-7289
- Others
By Application
- Hospital
- Clinic
- Others
A full report of Post Polycythemia Vera Myelofibrosis (PPV MF) Market is available at: https://www.omrglobal.com/industry-reports/post-polycythemia-vera-myelofibrosis-ppv-mf-market
Post Polycythemia Vera Myelofibrosis (PPV MF) Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Incyte Corp.
- Italfarmaco SpA
- JW Pharmaceutical Corp.
- Kartos Therapeutics Inc.
- Karyopharm Therapeutics Inc.
- Lynk Pharmaceutical Hangzhou Co. Ltd.
- Medimmune LLC
- MEI Pharma Inc.
- Merck & Co Inc.
- Novartis AG
- NS Pharma Inc.
- Promedior Inc.
- Rhizen Pharmaceuticals AG
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
